KYTX logo

Kyverna Therapeutics (KYTX) Financials

Balance sheets

Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 1, 2023Jun 1, 2023Mar 1, 2023Dec 1, 2022

Total Assets

$339.2 M(-6.6%)$363.1 M(-6.9%)$390.0 M(+418.6%)$75.2 M(-18.7%)$92.5 M--$66.9 M

Current Assets

$325.4 M(-6.7%)$348.8 M(-7.1%)$375.5 M(+519.0%)$60.7 M(-23.6%)$79.4 M--$53.3 M

Non Current Assets

$13.8 M(-3.3%)$14.3 M(-1.4%)$14.5 M(-0.2%)$14.5 M(+11.1%)$13.1 M--$13.7 M

Total Liabilities

$36.5 M(+23.2%)$29.6 M(+2.1%)$29.0 M(-86.0%)$206.6 M(+1.1%)$204.3 M--$140.9 M

Current Liabilities

$31.0 M(+32.0%)$23.5 M(+7.4%)$21.9 M(+10.1%)$19.9 M(+17.7%)$16.9 M--$12.0 M

Long Term Liabilities

$5.5 M(-10.3%)$6.1 M(-14.0%)$7.1 M(-96.2%)$186.7 M(-0.4%)$187.4 M--$129.0 M

Shareholders Equity

$302.7 M(-9.2%)$333.5 M(-7.6%)$361.0 M(+374.7%)-$131.4 M(-17.5%)-$111.8 M---$74.0 M

Book Value

$302.7 M(-9.2%)$333.5 M(-7.6%)$361.0 M(+374.7%)-$131.4 M(-17.5%)-$111.8 M---$74.0 M

Working Capital

$294.4 M(-9.5%)$325.3 M(-8.0%)$353.6 M(+766.6%)$40.8 M(-34.8%)$62.5 M--$41.3 M

Cash And Cash Equivalents

$104.7 M(-20.5%)$131.6 M(-41.3%)$224.3 M(+547.4%)$34.6 M(+50.9%)$23.0 M--$37.7 M

Accounts Payable

$9.9 M(+104.3%)$4.9 M(-34.8%)$7.5 M(+71.0%)$4.4 M(+44.2%)$3.0 M--$1.5 M

Accounts Receivable

--------

Short Term Debt

$3.9 M(+1.6%)$3.9 M(+4.1%)$3.7 M(+27.3%)$2.9 M(+4.4%)$2.8 M--$2.3 M

Long Term Debt

$5.2 M(-15.1%)$6.1 M(-14.0%)$7.1 M(+15.7%)$6.2 M(-10.0%)$6.8 M--$8.3 M

Total Debt

$9.1 M(-8.6%)$10.0 M(-7.8%)$10.8 M(+19.5%)$9.1 M(-5.8%)$9.6 M(+100.0%)$0.0(0%)$0.0(-100.0%)$10.6 M

Debt To Equity

0.0(0%)0.0(0%)0.0(+142.9%)-0.1(+22.2%)-0.1--0.0

Current Ratio

10.5(-29.3%)14.9(-13.4%)17.2(+462.9%)3.0(-35.2%)4.7--4.5

Quick Ratio

--------

Inventory

--------

Retained Earnings

-$226.0 M(-18.0%)-$191.5 M(-17.7%)-$162.7 M(-19.6%)-$136.0 M(-17.9%)-$115.4 M---$75.7 M

PB Ratio

0.7(-27.8%)1.0(-67.3%)3.0-----

Income statements

Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 1, 2023Jun 1, 2023Mar 1, 2023Dec 1, 2022

EPS

-$0.8(-19.4%)-$0.7(+40.2%)-$1.1(-121.2%)-$0.5(-33.7%)-$0.4(-18.1%)-$0.3(+25.7%)-$0.4(-31.1%)-$0.3

TTM EPS

-$3.1(-15.8%)-$2.7(-15.0%)-$2.3(-42.0%)-$1.6(-12.1%)-$1.5(-35.0%)-$1.1(-42.1%)-$0.8(-131.1%)-$0.3

Revenue

-------$282.0 K

TTM Revenue

-------$282.0 K

Total Expenses

$38.8 M(+16.0%)$33.4 M(+13.9%)$29.4 M(+37.3%)$21.4 M(+31.3%)$16.3 M(+22.4%)$13.3 M(+16.2%)$11.4 M(+26.4%)$9.1 M

Operating Expenses

$38.8 M(+16.0%)$33.4 M(+13.9%)$29.4 M(+37.3%)$21.4 M(+31.3%)$16.3 M(+22.4%)$13.3 M(+16.2%)$11.4 M(+26.4%)$9.1 M

Cost Of Goods Sold

--------

TTM Cost Of Goods Sold

--------

Gross Profit

--------

TTM Gross Profit

--------

Gross Margin

--------

Operating Profit

-$38.8 M(-16.0%)-$33.4 M(-13.9%)-$29.4 M(-37.3%)-$21.4 M(-31.3%)-$16.3 M(-22.4%)-$13.3 M(-16.2%)-$11.4 M(-30.4%)-$8.8 M

TTM Operating Profit

-$122.9 M(-22.4%)-$100.5 M(-25.1%)-$80.3 M(-28.7%)-$62.4 M(-25.3%)-$49.8 M(-48.6%)-$33.5 M(-65.8%)-$20.2 M(-130.4%)-$8.8 M

Operating Margin

--------3111.7%

Net Income

-$34.5 M(-19.8%)-$28.8 M(-7.9%)-$26.7 M(-29.2%)-$20.7 M(-33.6%)-$15.5 M(-18.1%)-$13.1 M(-17.5%)-$11.1 M(-31.2%)-$8.5 M

TTM Net Income

-$110.7 M(-20.8%)-$91.6 M(-20.7%)-$75.9 M(-25.8%)-$60.4 M(-25.3%)-$48.2 M(-47.3%)-$32.7 M(-66.7%)-$19.6 M(-131.2%)-$8.5 M

Net Margin

--------3012.8%

EBIT

-$34.5 M(-19.8%)-$28.8 M(-7.9%)-$26.6 M(-29.2%)-$20.6 M(-33.8%)-$15.4 M(-18.2%)-$13.0 M(-17.5%)-$11.1 M(-31.3%)-$8.5 M

TTM EBIT

-$110.5 M(-20.8%)-$91.4 M(-20.8%)-$75.7 M(-25.8%)-$60.2 M(-25.3%)-$48.0 M(-47.3%)-$32.6 M(-66.7%)-$19.6 M(-131.3%)-$8.5 M

EBITDA

-$33.9 M(-20.1%)-$28.2 M(-7.9%)-$26.2 M(-29.8%)-$20.2 M(-34.6%)-$15.0 M(-18.6%)-$12.6 M(-18.0%)-$10.7 M(-32.5%)-$8.1 M

TTM EBITDA

-$108.5 M(-21.1%)-$89.5 M(-21.1%)-$73.9 M(-26.4%)-$58.5 M(-26.0%)-$46.4 M(-47.7%)-$31.4 M(-67.2%)-$18.8 M(-132.5%)-$8.1 M

Selling, General & Administrative Expenses

$9.6 M(+56.6%)$6.1 M(-11.2%)$6.9 M(+63.3%)$4.2 M(+59.7%)$2.6 M(-8.9%)$2.9 M(+6.0%)$2.7 M(+37.4%)$2.0 M

TTM SGA

$26.8 M(+35.0%)$19.8 M(+19.3%)$16.6 M(+33.2%)$12.5 M(+21.7%)$10.3 M(+34.6%)$7.6 M(+61.3%)$4.7 M(+137.4%)$2.0 M

Depreciation And Amortization

$558.0 K(+5.3%)$530.0 K(+10.0%)$482.0 K(+4.3%)$462.0 K(+5.5%)$438.0 K(+6.0%)$413.0 K(+4.8%)$394.0 K-

TTM D&A

$2.0 M(+6.3%)$1.9 M(+6.5%)$1.8 M(+5.2%)$1.7 M(+37.1%)$1.2 M(+54.3%)$807.0 K(+104.8%)$394.0 K-

Interest Expense

$32.0 K(-17.9%)$39.0 K(-11.4%)$44.0 K(-6.4%)$47.0 K(-6.0%)$50.0 K(+8.7%)$46.0 K(+4.5%)$44.0 K(+7.3%)$41.0 K

TTM Interest Expense

$162.0 K(-10.0%)$180.0 K(-3.7%)$187.0 K(0%)$187.0 K(+3.3%)$181.0 K(+38.2%)$131.0 K(+54.1%)$85.0 K(+107.3%)$41.0 K

Income Tax

--------

TTM Income Tax

--------

PE Ratio

--------

PS Ratio

--------

Cashflow statements

Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 1, 2023Jun 1, 2023Mar 1, 2023Dec 1, 2022

Cash From Operations

-$27.5 M(-13.7%)-$24.2 M(+5.3%)-$25.5 M(-37.5%)-$18.6 M(-66.8%)-$11.1 M(+1.1%)-$11.3 M(+1.8%)-$11.5 M-

TTM CFO

-$95.8 M(-20.6%)-$79.4 M(-19.4%)-$66.5 M(-26.8%)-$52.4 M(-54.8%)-$33.8 M(-49.0%)-$22.7 M(-98.3%)-$11.5 M-

Cash From Investing

$676.0 K(+101.0%)-$67.9 M(+44.7%)-$122.9 M(-487.9%)$31.7 M(+158.5%)-$54.1 M(-1803833.3%)-$3000.0(-100.0%)$13.7 M-

TTM CFI

-$158.4 M(+25.7%)-$213.2 M(-46.7%)-$145.3 M(-1554.2%)-$8.8 M(+78.3%)-$40.5 M(-396.4%)$13.7 M(-0.0%)$13.7 M-

Cash From Financing

-$152.0 K(+73.3%)-$569.0 K(-100.2%)$338.0 M(+23673.8%)-$1.4 M(-104.1%)$34.8 M(+39.7%)$24.9 M(+17395.8%)-$144.0 K-

TTM CFF

$335.9 M(-9.4%)$370.8 M(-6.4%)$396.3 M(+581.9%)$58.1 M(-2.4%)$59.6 M(+140.5%)$24.8 M(+17295.8%)-$144.0 K-

Free Cash Flow

-$27.6 M(-9.5%)-$25.2 M(+3.3%)-$26.1 M(-38.0%)-$18.9 M(-65.9%)-$11.4 M(-1.1%)-$11.3 M(+2.0%)-$11.5 M-

TTM FCF

-$97.8 M(-19.9%)-$81.6 M(-20.6%)-$67.6 M(-27.5%)-$53.0 M(-55.4%)-$34.1 M(-50.1%)-$22.7 M(-98.0%)-$11.5 M-

CAPEX

--------

TTM CAPEX

--------

Dividends Paid

--------

TTM Dividends Paid

--------

TTM Dividend Per Share

--------

TTM Dividend Yield

--------

Payout Ratio

--------